Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Rydapt
Pharma
Astellas’ Xospata wins AML approval, with Daiichi close behind
Astellas will likely soon be joined by Daiichi in relapsed/refractory FLT3-mutated AML, and both have eyes on Novartis' Rydapt.
Angus Liu
Nov 29, 2018 10:31am
NICE issues early 'no' on RoActemra, Rydapt
Dec 6, 2017 12:00pm
Novartis wins FDA nod for Rydapt, new targeted drug for AML
Apr 28, 2017 11:36am